Apogee Therapeutics Inc. (NASDAQ:APGE) is a top oversold NASDAQ stock to buy now, with BTIG analyst raising price target to $115. The company has $681.4 million in cash, cash equivalents, and marketable securities, supporting its operating expenses into the first quarter of 2028. Apogee offers treatments for COPD, AD, and I&I indications.

Analyst notes EASI-75 breakthrough for Biologics in Atopic Dermatitis, exceeding expectations and painting a positive picture for Apogee Therapeutics Inc. (NASDAQ:APGE). The company is positioned as a leader with a market-leading profile and strong potential for growth.

Investors are encouraged to consider APGE as an investment, but certain AI stocks may offer greater upside potential with less downside risk. A free report on the best short-term AI stock is available for those looking to capitalize on undervalued opportunities.

Read more at Yahoo Finance: BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating